Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Lin, Albert C C ^a,b   Dissanayake, Dilan ^a,b   Dhanji, Salim ^a   Elford, Alisha R ^a   Ohashi, Pamela S ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; ALPHA INTERFERON; CYTOKINE; GLYCOPROTEIN; LIPOPOLYSACCHARIDE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; DIMERIZATION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; METABOLISM;

MURINAE;

ANIMALS; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; GLYCOPROTEINS; IMMUNE TOLERANCE; INTERFERON-ALPHA; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; TOLL-LIKE RECEPTORS;

EID: 80052611973     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023940     Document Type: Article

References (70)

1. Kawai T, Akira S, (2007) Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13: 460-469.
2. Iwasaki A, Medzhitov R, (2010) Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
3. Banchereau J, Pascual V, (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392.
4. Blanco P, Palucka AK, Pascual V, Banchereau J, (2008) Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 19: 41-52.
5. Garza KM, Chan SM, Suri R, Nguyen LT, Odermatt B, et al. (2000) Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med 191: 2021-2027.
6. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, et al. (2005) Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11: 138-145.
7. Waldner H, Collins M, Kuchroo VK, (2004) Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest 113: 990-997.
8. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, et al. (2003) Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9: 1484-1490.
9. Gonnella PA, Waldner H, Del Nido PJ, McGowan FX, (2008) Inhibition of experimental autoimmune myocarditis: peripheral deletion of TcR Vbeta 8.1, 8.2+ CD4+ T cells in TLR-4 deficient mice. J Autoimmun 31: 180-187.
10. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A, (2005) Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 204: 27-42.
11. Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ, et al. (2001) Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 69: 1477-1482.
12. Re F, Strominger JL, (2001) Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276: 37692-37699.
13. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, et al. (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443-451.
14. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, et al. (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424: 743-748.
15. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, et al. (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643.
16. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, et al. (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
17. Guiducci C, Ott G, Chan JH, Damon E, Calacsan C, et al. (2006) Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 203: 1999-2008.
18. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, et al. (2005) Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434: 1035-1040.
19. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
20. Ma X, Trinchieri G, (2001) Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol 79: 55-92.
21. Joffre O, Nolte MA, Sporri R, Reis e Sousa C, (2009) Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 227: 234-247.
22. Skokos D, Nussenzweig MC, (2007) CD8- DCs induce IL-12-independent Th1 differentiation through Delta 4 Notch-like ligand in response to bacterial LPS. J Exp Med 204: 1525-1531.
23. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, et al. (2006) Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211: 81-92.
24. Haddad W, Cooper CJ, Zhang Z, Brown JB, Zhu Y, et al. (2003) P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J Exp Med 198: 369-377.
25. Knippertz I, Hesse A, Schunder T, Kampgen E, Brenner MK, et al. (2009) Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother 32: 524-538.
26. Su Z, Frye C, Bae KM, Kelley V, Vieweg J, (2008) Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions. Clin Cancer Res 14: 6207-6217.
27. Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI, (2000) Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. Diabetes 49: 1106-1115.
28. Liu J, Beller DI, (2003) Distinct pathways for NF-kappa B regulation are associated with aberrant macrophage IL-12 production in lupus- and diabetes-prone mouse strains. J Immunol 170: 4489-4496.
29. Grabie N, Delfs MW, Westrich JR, Love VA, Stavrakis G, et al. (2003) IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. J Clin Invest 111: 671-680.
30. Trembleau S, Penna G, Gregori S, Giarratana N, Adorini L, (2003) IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. J Immunol 170: 5491-5501.
31. Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, et al. (2003) Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes. Ann N Y Acad Sci 1005: 409-411.
32. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, et al. (2004) Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351: 2069-2079.
33. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, et al. (2003) Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198: 1951-1957.
34. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
35. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569.
36. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, et al. (1991) Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65: 305-317.
37. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
38. Mescher MF, Agarwal P, Casey KA, Hammerbeck CD, Xiao Z, et al. (2007) Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation. Semin Immunol 19: 153-161.
39. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM, (1989) Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342: 559-561.
40. Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, et al. (2006) Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol 177: 7551-7558.
41. Akira S, Hemmi H, (2003) Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85: 85-95.
42. Cousens LP, Orange JS, Su HC, Biron CA, (1997) Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection. Proc Natl Acad Sci U S A 94: 634-639.
43. Aichele P, Unsoeld H, Koschella M, Schweier O, Kalinke U, et al. (2006) CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J Immunol 176: 4525-4529.
44. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K, (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202: 637-650.
45. Barrat FJ, Coffman RL, (2008) Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 223: 271-283.
46. Nitta Y, Kawamoto S, Tashiro F, Aihara H, Yoshimoto T, et al. (2001) IL-12 plays a pathologic role at the inflammatory loci in the development of diabetes in NOD mice. J Autoimmun 16: 97-104.
47. Monteiro JM, Harvey C, Trinchieri G, (1998) Role of interleukin-12 in primary influenza virus infection. J Virol 72: 4825-4831.
48. Orange JS, Biron CA, (1996) An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J Immunol 156: 1138-1142.
49. Schijns VE, Haagmans BL, Wierda CM, Kruithof B, Heijnen IA, et al. (1998) Mice lacking IL-12 develop polarized Th1 cells during viral infection. J Immunol 160: 3958-3964.
50. Oxenius A, Karrer U, Zinkernagel RM, Hengartner H, (1999) IL-12 is not required for induction of type 1 cytokine responses in viral infections. J Immunol 162: 965-973.
51. Cousens LP, Peterson R, Hsu S, Dorner A, Altman JD, et al. (1999) Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J Exp Med 189: 1315-1328.
52. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, et al. (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-1602.
53. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J, (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294: 1540-1543.
54. Kono DH, Baccala R, Theofilopoulos AN, (2003) Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity 36: 503-510.
55. Sporri R, Reis e Sousa C, (2005) Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 6: 163-170.
56. Devendra D, Jasinski J, Melanitou E, Nakayama M, Li M, et al. (2005) Interferon-alpha as a mediator of polyinosinic:polycytidylic acid-induced type 1 diabetes. Diabetes 54: 2549-2556.
57. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, et al. (2006) Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 116: 2456-2463.
58. Lang PA, Cervantes-Barragan L, Verschoor A, Navarini AA, Recher M, et al. (2009) Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. Blood 113: 1045-1052.
59. Jiang A, Bloom O, Ono S, Cui W, Unternaehrer J, et al. (2007) Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 27: 610-624.
60. Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, et al. (2002) Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 195: 15-21.
61. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, et al. (2003) Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18: 605-617.
62. Reis e Sousa C, (2006) Dendritic cells in a mature age. Nat Rev Immunol 6: 476-483.
63. Kaka AS, Foster AE, Weiss HL, Rooney CM, Leen AM, (2008) Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother 31: 359-369.
64. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, et al. (1996) IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 4: 471-481.
65. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, et al. (1996) Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 26: 1553-1559.
66. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, et al. (2004) Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 172: 2827-2833.
67. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
68. Weidt G, Deppert W, Utermohlen O, Heukeshoven J, Lehmann-Grube F, (1995) Emergence of virus escape mutants after immunization with epitope vaccine. J Virol 69: 7147-7151.
69. Battegay M, Cooper S, Althage A, Banziger J, Hengartner H, et al. (1991) Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J Virol Methods 33: 191-198.
70. Nguyen LT, Elford AR, Murakami K, Garza KM, Schoenberger SP, et al. (2002) Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 195: 423-435.